The fascination of Yale professor Craig Crews with a natural product compound led a decade later to the approval this summer of a brand-new treatment for multiple myeloma.
The story of how a novel kind of cancer drug, carfilzomib, was born from academic curiosity is the subject of a profile in Aug. 27 issue of the journal Chemical & Engineering News.
“This a great example of how university research can be translated into a medical therapy,” said Crews. “Too often promising ideas get lost in what drug companies call the valley of death.”
Health & Medicine
Bill Hathaway: email@example.com, 203-432-1322